

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Positive Profit Alert

This announcement is made by Regent Pacific Group Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company wishes to inform shareholders and potential investors of the Company that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group and the information currently available, the Group expects to record a profit for the period ended 30 June 2026 (the “**Reporting Period**”) of between approximately US\$0.50 million (or approximately HK\$3.90 million) and approximately US\$1.00 million (or approximately HK\$7.80 million). This represents a substantial improvement compared to a loss of approximately US\$2.22 million (or approximately HK\$17.32 million) for the corresponding period in 2025 (the “**Corresponding Period**”).

The improvement in profit for the Reporting Period, as compared to the Corresponding Period, is mainly attributable to the following:

- (a) the Group recorded a net milestone payment of US\$4.50 million (or approximately HK\$35.10 million) recognised as income in the Reporting Period, with the cash consideration receivable in the second half of 2026, from 復星萬邦(江蘇)醫藥集團有限公司 (Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.), following New Drug Application approval for Senstend™, after deduction of withholding tax in the People’s Republic of China (Corresponding Period: nil); and
- (b) the Group recorded an impairment loss of approximately US\$1.00 million (or approximately HK\$7.80 million) on right-of-use asset relating to the Group’s Hong Kong office lease (Corresponding Period: nil).

All other items comprising the profit for the Reporting Period were broadly consistent with those for the Corresponding Period.

The Company is in the process of finalising the Group's interim results for the Reporting Period. The information contained in this announcement is based solely on a preliminary assessment of the unaudited consolidated management accounts of the Group for the Reporting Period and information currently available. It has not been finalised or reviewed by the Company's auditors or the Audit Committee of the Company and may therefore be subject to adjustment. Shareholders and potential investors of the Company should refer to the announcement of the Group's unaudited consolidated interim results for the Reporting Period, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified, amounts denominated in US\$ have been translated into HK\$, for illustrative purposes only, at the exchange rate of US\$1.00 = HK\$7.80.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 3 August 2026

As at the date of this announcement, the Board comprises six Directors:

Executive Director:

Jamie Gibson (*Chief Executive Officer*)

Non-Executive Directors:

James Mellon (*Chairman*)

Jayne Sutcliffe

Independent Non-Executive Directors:

Mark Searle

Adrian Chan

Ihsan Al Chalabi